ClinicalTrials.gg
CompletedNCT01634165Updated Oct 7, 2014Results posted

A Study of LY2963016 in Healthy Participants

A Phase 1 interventional study of LY2963016 and Lantus in Healthy Volunteers, sponsored by Eli Lilly and Company. Completed at 1 site in Singapore. Open to participants aged 21 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-10-07.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
21 Years to 65 Years
Sex
All
01

Study summary

This study involves 2 single injections of LY2963016 and 2 single injections of Lantus. There will be at least 6 days between each injection.

The study will compare LY2963016 to Lantus at two different doses.

This study is approximately 10 weeks long, not including screening. Screening is required within 4 weeks of the start of the study.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,111 studies on the registry; 154 are open to participants now.

Of its 541 completed or terminated interventional studies of FDA-regulated products, 358 (66%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy males or females
  • Women must be either surgically sterile, , or agree to use a reliable method of during the study
  • Have a between 18.5 and 29.9 kilograms per meter squared (kg/m²)
  • Are nonsmokers and have not smoked for at least 6 months prior to entering the study
  • Have normal blood pressures and pulse rates at screening, as determined by the investigator
  • Have an (ECG) at screening considered as within normal limits by the investigator
  • Have clinical laboratory test results within normal reference range for the population
  • Have fasting plasma glucose \<110 milligrams per deciliter (mg/dL) (\<6.0 micromoles per liter [mmol/L]) at screening
  • Have venous access sufficient to allow for blood sampling, intravenous drug administration, and clamp procedures as per the protocol
  • Have given written approved by Lilly and the ethical review board (ERB) governing the site

Exclusion criteria

Exclusion Criteria:

  • Are persons who have previously completed or withdrawn from this study
  • Are currently enrolled in or have discontinued within the last 30 days from a clinical trial involving an drug or device or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study
  • Have known allergies to insulin, its , or related drugs or have history of relevant allergic reactions of any origin
  • Have significant history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the study medication; or of interfering with the interpretation of data
  • Show evidence of significant active neuropsychiatric disease
  • Show evidence of current use of known drugs of abuse or have a history of use within the past year
  • Have a history of first-degree relatives known to have diabetes mellitus
  • Show evidence of an acute infection with fever or infectious disease at the time of study entry
  • Show evidence of (HIV) infection and/or positive human HIV antibodies at screening
  • Have positive surface antigens at screening
  • Intend to use over-the-counter medication within 7 days or prescription medication within 14 days prior to dosing (apart from vitamin/mineral supplements, occasional paracetamol, thyroid replacement, or methods)
  • Have donated blood or had a blood loss of 450 milliliters (mL) 3 months prior to study enrollment
  • Have an average weekly alcohol intake that exceeds 21 units per week (males) and 14 units per week (females) or are unwilling to stop alcohol consumption from 48 hours prior to each dosing until discharged from the clinical research unit (CRU)
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    0.3 U/kg LY2963016

    Single 0.3 units/kilogram (U/kg) subcutaneous dose of LY2963016

    Drug: LY2963016

  • Experimental
    0.3 U/kg Lantus

    Single 0.3 U/kg subcutaneous dose of Lantus

    Drug: Lantus

  • Experimental
    0.6 U/kg LY2963016

    Single 0.6 U/kg subcutaneous dose of LY2963016

    Drug: LY2963016

  • Experimental
    0.6 U/kg Lantus

    Single 0.6 U/kg subcutaneous dose of Lantus

    Drug: Lantus

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics: Area Under the Serum LY2963016 or Lantus Concentration-Time Curve (AUC) From Zero to Infinity [AUC(0-∞)]

    Results for LY2936016 treatment arms provide the AUC(0-∞) data for LY2936016, while the results for Lantus treatment arms provide the AUC(0-∞) for Lantus.

    Time frame: Predose up to 24 hours after administration of study drug

  2. Pharmacokinetics: Maximum Serum LY2963016 or Lantus Concentration (Cmax)

    Time frame: Predose up to 24 hours after administration of study drug

Secondary outcomes

  1. Pharmacokinetics: Area Under the Serum Concentration-Time Curve From Time Zero to 24 Hours [AUC(0-24)] of LY2963016 or Lantus

    Results for LY2936016 treatment arms provide the AUC(0-24) data for LY2936016, while the results for Lantus treatment arms provide the AUC(0-24) for Lantus.

    Time frame: Predose up to 24 hours after administration of study drug

  2. Pharmacokinetics: Area Under the Serum Concentration-Time Curve (AUC) From Time Zero to Last Measured Concentration Value [AUC(0-tlast)] of LY2963016 or Lantus

    Results for LY2936016 treatment arms provide the AUC(0-tlast) data for LY2936016, while the results for Lantus treatment arms provide the AUC(0-tlast) for Lantus.

    Time frame: Predose up to 24 hours after administration of study drug

  3. Maximum Glucose Infusion Rate (Rmax)

    Rmax is used to measure the study drug action over time as measured by the euglycaemic clamp procedure. During the euglycaemic clamp procedure, blood glucose concentrations are held constant after the administration of LY2963016 or Lantus by adjusting the exogenous glucose infusion rate.

    Time frame: Postdose up to 24 hours after administration of study drug

  4. Total Amount of Glucose Infused (Gtot)

    Gtot is used to measure the study drug action over time as measured by the euglycaemic clamp procedure. During the euglycaemic clamp procedure, blood glucose concentrations are held constant after the administration of LY2963016 or Lantus by adjusting the exogenous glucose infusion rate.

    Time frame: Postdose up to 24 hours after administration of study drug

07

Results

Posted Oct 7, 2014

Participant flow

Period 1
Participant flow — Period 1
Milestone0.3 U/kg LY, 0.6 U/kg LY, 0.3 U/kg Lantus, 0.6 U/kg Lantus0.6 U/kg LY, 0.6 U/kg Lantus, 0.3 U/kg LY, 0.3 U/kg Lantus0.3 U/kg Lantus, 0.3 U/kg LY, 0.6 U/kg Lantus, 0.6 U/kg LY0.6 U/kg Lantus, 0.3 U/kg Lantus, 0.6 U/kg LY, 0.3 U/kg LY
Started6666
Received at least 1 dose of study drug6666
Completed6666
Not completed0000
Period 2
Participant flow — Period 2
Milestone0.3 U/kg LY, 0.6 U/kg LY, 0.3 U/kg Lantus, 0.6 U/kg Lantus0.6 U/kg LY, 0.6 U/kg Lantus, 0.3 U/kg LY, 0.3 U/kg Lantus0.3 U/kg Lantus, 0.3 U/kg LY, 0.6 U/kg Lantus, 0.6 U/kg LY0.6 U/kg Lantus, 0.3 U/kg Lantus, 0.6 U/kg LY, 0.3 U/kg LY
Started6666
Completed6566
Not completed0100
Withdrew: Adverse event0100
Period 3
Participant flow — Period 3
Milestone0.3 U/kg LY, 0.6 U/kg LY, 0.3 U/kg Lantus, 0.6 U/kg Lantus0.6 U/kg LY, 0.6 U/kg Lantus, 0.3 U/kg LY, 0.3 U/kg Lantus0.3 U/kg Lantus, 0.3 U/kg LY, 0.6 U/kg Lantus, 0.6 U/kg LY0.6 U/kg Lantus, 0.3 U/kg Lantus, 0.6 U/kg LY, 0.3 U/kg LY
Started6566
Completed6566
Not completed0000
Period 4
Participant flow — Period 4
Milestone0.3 U/kg LY, 0.6 U/kg LY, 0.3 U/kg Lantus, 0.6 U/kg Lantus0.6 U/kg LY, 0.6 U/kg Lantus, 0.3 U/kg LY, 0.3 U/kg Lantus0.3 U/kg Lantus, 0.3 U/kg LY, 0.6 U/kg Lantus, 0.6 U/kg LY0.6 U/kg Lantus, 0.3 U/kg Lantus, 0.6 U/kg LY, 0.3 U/kg LY
Started6566
Completed6566
Not completed0000

Outcome measures

PrimaryPharmacokinetics: Area Under the Serum LY2963016 or Lantus Concentration-Time Curve (AUC) From Zero to Infinity [AUC(0-∞)]

Results for LY2936016 treatment arms provide the AUC(0-∞) data for LY2936016, while the results for Lantus treatment arms provide the AUC(0-∞) for Lantus.

Time frame:
Predose up to 24 hours after administration of study drug
Reported as:
Geometric mean · picomoles*hour per liter (pmol*h/L)
Pharmacokinetics: Area Under the Serum LY2963016 or Lantus Concentration-Time Curve (AUC) From Zero to Infinity [AUC(0-∞)]
picomoles*hour per liter (pmol*h/L)0.3 U/kg LY29630160.6 U/kg LY29630160.3 U/kg Lantus0.6 U/kg Lantus
Pharmacokinetics: Area Under the Serum LY2963016 or Lantus Concentration-Time Curve (AUC) From Zero to Infinity [AUC(0-∞)]2330 ± 394470 ± 152390 ± 334310 ± 51
PrimaryPharmacokinetics: Maximum Serum LY2963016 or Lantus Concentration (Cmax)
Time frame:
Predose up to 24 hours after administration of study drug
Reported as:
Geometric mean · picomoles per liter (pmol/L)
Pharmacokinetics: Maximum Serum LY2963016 or Lantus Concentration (Cmax)
picomoles per liter (pmol/L)0.3 U/kg LY29630160.6 U/kg LY29630160.3 U/kg Lantus0.6 U/kg Lantus
Pharmacokinetics: Maximum Serum LY2963016 or Lantus Concentration (Cmax)108 ± 20180 ± 28105 ± 33174 ± 38
SecondaryPharmacokinetics: Area Under the Serum Concentration-Time Curve From Time Zero to 24 Hours [AUC(0-24)] of LY2963016 or Lantus

Results for LY2936016 treatment arms provide the AUC(0-24) data for LY2936016, while the results for Lantus treatment arms provide the AUC(0-24) for Lantus.

Time frame:
Predose up to 24 hours after administration of study drug
Reported as:
Geometric mean · picomoles*hour per liter (pmol*h/L)
Pharmacokinetics: Area Under the Serum Concentration-Time Curve From Time Zero to 24 Hours [AUC(0-24)] of LY2963016 or Lantus
picomoles*hour per liter (pmol*h/L)0.3 U/kg LY29630160.6 U/kg LY29630160.3 U/kg Lantus0.6 U/kg Lantus
Pharmacokinetics: Area Under the Serum Concentration-Time Curve From Time Zero to 24 Hours [AUC(0-24)] of LY2963016 or Lantus1730 ± 203160 ± 271690 ± 302940 ± 45
SecondaryPharmacokinetics: Area Under the Serum Concentration-Time Curve (AUC) From Time Zero to Last Measured Concentration Value [AUC(0-tlast)] of LY2963016 or Lantus

Results for LY2936016 treatment arms provide the AUC(0-tlast) data for LY2936016, while the results for Lantus treatment arms provide the AUC(0-tlast) for Lantus.

Time frame:
Predose up to 24 hours after administration of study drug
Reported as:
Geometric mean · picomoles*hour per liter (pmol*h/L)
Pharmacokinetics: Area Under the Serum Concentration-Time Curve (AUC) From Time Zero to Last Measured Concentration Value [AUC(0-tlast)] of LY2963016 or Lantus
picomoles*hour per liter (pmol*h/L)0.3 U/kg LY29630160.6 U/kg LY29630160.3 U/kg Lantus0.6 U/kg Lantus
Pharmacokinetics: Area Under the Serum Concentration-Time Curve (AUC) From Time Zero to Last Measured Concentration Value [AUC(0-tlast)] of LY2963016 or Lantus1730 ± 203160 ± 271670 ± 282940 ± 45
SecondaryMaximum Glucose Infusion Rate (Rmax)

Rmax is used to measure the study drug action over time as measured by the euglycaemic clamp procedure. During the euglycaemic clamp procedure, blood glucose concentrations are held constant after the administration of LY2963016 or Lantus by adjusting the exogenous glucose infusion rate.

Time frame:
Postdose up to 24 hours after administration of study drug
Reported as:
Geometric mean · milligrams/kilograms/minute (mg/kg/min)
Maximum Glucose Infusion Rate (Rmax)
milligrams/kilograms/minute (mg/kg/min)0.3 U/kg LY29630160.6 U/kg LY29630160.3 U/kg Lantus0.6 U/kg Lantus
Maximum Glucose Infusion Rate (Rmax)1.81 ± 1003.05 ± 591.70 ± 923.25 ± 54
SecondaryTotal Amount of Glucose Infused (Gtot)

Gtot is used to measure the study drug action over time as measured by the euglycaemic clamp procedure. During the euglycaemic clamp procedure, blood glucose concentrations are held constant after the administration of LY2963016 or Lantus by adjusting the exogenous glucose infusion rate.

Time frame:
Postdose up to 24 hours after administration of study drug
Reported as:
Geometric mean · milligrams per kilograms (mg/kg)
Total Amount of Glucose Infused (Gtot)
milligrams per kilograms (mg/kg)0.3 U/kg LY29630160.6 U/kg LY29630160.3 U/kg Lantus0.6 U/kg Lantus
Total Amount of Glucose Infused (Gtot)1060 ± 1782260 ± 801050 ± 1302590 ± 62

Adverse events

Non-serious events are listed at a 4% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
0.3 U/kg LY2963016—0/23 (0%)4/23 (17.4%)
0.6 U/kg LY2963016—0/24 (0%)10/24 (41.7%)
0.3 U/kg Lantus—0/23 (0%)10/23 (43.5%)
0.6 U/kg Lantus—1/24 (4.2%)12/24 (50%)
Most frequent serious events
Most frequent serious events
Event0.3 U/kg LY29630160.6 U/kg LY29630160.3 U/kg Lantus0.6 U/kg Lantus
AnaemiaBlood and lymphatic system disorders0/230/240/231/24
Most frequent other events
Showing 10 of 25
Most frequent other events
Event0.3 U/kg LY29630160.6 U/kg LY29630160.3 U/kg Lantus0.6 U/kg Lantus
Procedural painInjury, poisoning and procedural complications1/231/244/232/24
Post procedural swellingInjury, poisoning and procedural complications1/232/243/231/24
Application site haematomaGeneral disorders1/231/242/233/24
VomitingGastrointestinal disorders0/232/240/231/24
DizzinessNervous system disorders0/230/241/232/24
Abdominal distensionGastrointestinal disorders0/230/241/230/24
NauseaGastrointestinal disorders0/230/241/230/24
Joint swellingMusculoskeletal and connective tissue disorders0/230/241/230/24
HeadacheNervous system disorders0/231/241/230/24
RhinorrhoeaRespiratory, thoracic and mediastinal disorders1/230/241/231/24

Baseline characteristics

Participants who received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)All Participants
Mean32.1 ± 7.7
Sex: Female, Male
Sex: Female, Male(Participants)All Participants
Female4
Male20
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)All Participants
Asian24
Region of Enrollment
Region of Enrollment(participants)All Participants
Singapore24
08

Study locations

1 site
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Singapore, 117597, Singapore
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2012, a primary completion of Sep 2012 and a completion of Sep 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2014, 2 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 2, 2012
First posted
Jul 6, 2012
Start
Jul 2012
Primary completionActual
Sep 2012
CompletionActual
Sep 2012
Results first posted
Oct 7, 2014
Last update
Oct 7, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 7, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01634165
Responsible party
Sponsor
First posted
Jul 6, 2012
Start date
Jul 2012
Primary completion
Sep 2012
Completion
Sep 2012
Results posted
Oct 7, 2014
Last update
Oct 7, 2014

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin Glargine

Start the discussion